跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Recombinant HPV 16 E7 fusion protein vaccine
首页
药物
Recombinant HPV 16 E7 fusion protein vaccine
Recombinant HPV 16 E7 fusion protein vaccine
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
Human papilloma virus and heat shock protein recombinant protein vaccine and use thereof
申请人: TUMOUR INST TUMOUR HOSPITAL CH
优先权: 2005
CN
MATV51 recombinant adenovirus vector, application, preparation method and HPV16/18/52 therapeutic vaccine
申请人: AFFILIATED TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE OF HUAZHONG UNIV SCI & TECH
优先权: 2024
CN
Immunity enhancing therapeutic vaccine for HPV and related diseases
申请人: SHENZHEN TAILAI BIOPHARMACEUTICALS LLC
优先权: 2014
US
Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein
申请人: GENEMATRIX INC
优先权: 2020
US
Establishment and application of HPV16/18 tumor cell line and animal model of HPV16/18 tumor cell line
申请人: BEIJING XUNSHENG BIOMEDICAL RES CO LTD
优先权: 2022
CN
药物
反馈
